Etanercept

Etanercept (Enbrel^®) wurde im Februar 2000 in Deutschland zugelassen und ist als menschliches Tumornekrosefaktor-Rezeptor-Fusionsprotein nach Infliximab der zweite Vertreter der Antizytokine, die ein neues Behandlungsprinzip für die rheumatoide Arthritis darstellen.

Literatur

• 1 Feldmann M, Brennan F M, Maini R N. Rheumatoid arthritis.  Cell. 1996;  85 307-310
• 2 Culy C R, Keating G M. Etanercept: an updated review of its use in rheumatoid arthritis, psoriatic arthritis and juvenile rheumatoid arthritis.  Drugs. 2002;  62 2495-2539
• 3 Saxne T, Palladino M A, Heinegard D, Talal N, Wollheim F A. Detection of tumor necrosis factor alpha but not tumor necrosis factor beta in rheumatoid arthritis synovial fluid and serum.  Arthritis Rheum. 1988;  31 1041-1105
• 4 Beckham J C, Caldwell D S, Peterson B L, Pippen A M, Currie M S, Keefe F J, Weinberg J B. Disease severity in rheumatoid arthritis: relationships of plasma tumor necrosis factor-alpha, soluble interleukin 2-receptor, soluble CD4/CD8 ratio, neopterin, and fibrin D-dimer to traditional severity and functional measures.  J Clin Immunol. 1992;  12 353-361
• 5 Jarvis B, Faulds D. Etanercept: a review of its use in rheumatoid arthritis.  Drugs. 1999;  57 945-966
• 6 Choy E H, Panayi G S. Cytokine pathways and joint inflammation in rheumatoid arthritis.  N Engl J Med. 2001;  344 907-916
• 7 Cope A P, Aderka D, Doherty M, Engelmann H, Gibbons D, Jones A C, Brennan F M, Maini R N, Wallach D, Feldmann M. Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases.  Arthritis Rheum. 1992;  35 1160-1169
• 8 Elliott M J, Maini R N, Feldmann M, Long-Fox A, Charles P, Katsikis P, Brennan F M, Walker J, Bijl H, Ghrayeb J. et al . Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor alpha.  Arthritis Rheum. 1993;  36 1681-1690
• 9 Mohler K M, Torrance D S, Smith C A, Goodwin R G, Stremler K E, Fung V P, Madani H, Widmer M B. Soluble tumor necrosis factor (TNF) receptors are effective therapeutic agents in lethal endotoxemia and function simultaneously as both TNF carriers and TNF antagonists.  J Immunol. 1993;  151 1548-1561
• 10 Moreland L W, Baumgartner S W, Schiff M H, Tindall E A, Fleischmann R M, Weaver A L, Ettlinger R E, Cohen S, Koopman W J, Mohler K, Widmer M B, Blosch C M. Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein.  N Engl J Med. 1997;  337 141-147
• 11 Moreland L W, Schiff M H, Baumgartner S W, Tindall E A, Fleischmann R M, Bulpitt K J, Weaver A L, Keystone E C, Furst D E, Mease P J, Ruderman E M, Horwitz D A, Arkfeld D G, Garrison L, Burge D J, Blosch C M, Lange M L, McDonnell N D, Weinblatt M E. Etanercept therapy in rheumatoid arthritis. A randomized, controlled trial.  Ann Intern Med. 1999;  130 478-486
• 12 Weinblatt M E, Kremer J M, Bankhurst A D, Bulpitt K J, Fleischmann R M, Fox R I, Jackson C G, Lange M, Burge D J. A trial of etanercept, a recombinant tumor necrosis factor receptor:Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate.  N Engl J Med. 1999;  340 253-259
• 13 Bathon J M, Martin R W, Fleischmann R M, Tesser J R, Schiff M H, Keystone E C, Genovese M C, Wasko M C, Moreland L W, Weaver A L, Markenson J, Finck B K. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis.  N Engl J Med. 2000;  343 1586-1593
• 14 Genovese M C, Bathon J M, Martin R W, Fleischmann R M, Tesser J R, Schiff M H, Keystone E C, Wasko M C, Moreland L W, Weaver A L, Markenson J, Cannon G W, Spencer-Green G, Finck B K. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes.  Arthritis Rheum. 2002;  46 1443-1450
• 15 Lovell D J, Giannini E H, Reiff A, Cawkwell G D, Silverman E D, Nocton J J, Stein L D, Gedalia A, Ilowite N T, Wallace C A, Whitmore J, Finck B K. Pediatric Rheumatology Collaborative Study Group . Etanercept in children with polyarticular juvenile rheumatoid arthritis.  N Engl J Med. 2000;  342 763-769
• 16 Lovell D J, Giannini E H, Reiff A, Jones O Y, Schneider R, Olson J C, Stein L D, Gedalia A, Ilowite N T, Wallace C A, Lange M, Finck B K, Burge D J. Long-term efficacy and safety of etanercept in children with polyarticular-course juvenile rheumatoid arthritis: Interim results from an ongoing multicenter, open-label, extended-treatment trial.  Arthritis Rheum. 2003;  48 218-226
• 17 Mease P J, Goffe B S, Metz J, VanderStoep A, Finck B, Burge D J. Etanercept in the treatment of psoriatic arthritis and psoriasis: a randomised trial.  Lancet. 2000;  356 385-390
• 18 Rauchhaus M, Doehner W, Francis D P, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk H D, Coats A J, Anker S D. Plasma cytokine parameters and mortality in patients with chronic heart failure.  Circulation. 2000;  102 3060-3067
• 19 Anker S D, Coats A J. How to RECOVER from RENAISSANCE? The significance of the results of RECOVER, RENAISSANCE, RENEWAL and ATTACH.  Int J Cardiol. 2002;  86 123-130
• 20 Fachinformation Enbrel®. Wyeth Pharma GmbH 2003
• 21 Rote-Hand-Brief der Firmen ESSEX Pharma GmbH und Centocor zu Remicade® 31.01.2002
• 22 Manadan A M, Mohan A K, Cote T R, Siegel J N, Sequeira W, Block J A. Tuberculosis and Etanercept Treatment.  ACR Anual Scientific Meeting. 2002;  Abstract 356
• 23 Moreland L W, Bucy R P, Weinblatt M E, Mohler K M, Spencer-Green G T, Chatham W W. Immune function in patients with rheumatoid arthritis treated with etanercept.  Clin Immunol. 2002;  103 13-21
• 24 Cush J J, Kavanaugh A. FDA Meeting March 2003:. Update on the Safety of New Drugs for Rheumatoid Arthritis 2003
• 25 (http://www.rheumatology.org/research/hotline/0303TNFL.htm)
• 26 Rote-Hand-Brief der Firma Wyeth Pharma GmbH zu Enbrel® 06.02.2003
• 27 Cush J J, Matteson E L. FDA Advisory Committee Reviews Safety of TNF Inhibitors 2001. (http://www.rheumatology.org/research/hotline/0901tnf.html)
• 28 Mohan N, Edwards E T, Cupps T R, Slifman N R, Braun M M, Lee J, Siegel J N. Abstract 354 Leukocytoclastic Vasculitis Associated with Anti-tumor Necrosis Factor (TNF) Therapy. ACR Anual Scientific Meeting 2002